Table 5 Comparison with previous literatures adopting surgical excision with postoperative radiation therapy.
From: Optimizing surgical outcome of auricular keloid with a novel multimodal approach
Patient (N) | Keloid (N) | Ethnicity | Age (years) | Sex | Location | Prior OP | Surgery | External beam RT | RT regimen (total dose/fraction × dose per fraction) (Gy) | Recurrence rate (keloid N) | Follow-up (months) | Complication (keloid N) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
116 | 23 | 30 | NA | 28 | F (75%) M (35%) | Lobe (100%) | 33.3% (10/30) | Total excision | 6-MeV electron | 15/3 × 5; 1 Fr. in post-OP 2 h and 2 Fr. in post-OP 2–3 days | 13.3% (4/30) | 26 | Hyperpigmentation 13.3% (4/30) |
217 | 57 | 63 | NA | NA | F (91.2%) M (8.8%) | NA | 0% | Total excision: 59% (37/63) Enucleation: 41% (26/63) | 4-MeV electron | 15/3 × 5; over post-OP 3 days | 4.8% (3/63) (8.1% for total excision and 0% for enucleation) | 18 | No |
318 | 35 | NA | NA | 24 | F (97%) M (3%) | Lobe (100%) | All with OP or IL | Total excision | 100 kV X-ray photon | 10/1 × 10; within post-OP 24 h | 11.8% (4/34)a | 60 | Transient erythema and post-radiation hyperpigmentation |
419 | 145 | 174 | Japanese | NA | NA | Lobe (100%) | 13% (19/145) | Wedge excision + PS Simple excision + PS Simple excision + V–Y flap | 4-MeV electron | High dose: 15/3 × 5; over post-OP 3 days (20%) Low dose: 10/2 × 5; over post-OP 2 days (80%) | 4.0% (7/174) (4.7% for primary keloid and 0% for recurred keloid) | 18 | NA |
520 | 21 | NA | African | 22 | F (77.5%) M (22.5%) | Lobe (72%) Helix (28%) | 33.3% (7/21) | Total excision ± rhomboid flap | 100 kV X-ray photon | 12/3 × 4; each Fr. on post-OP 3rd, 4th, and 5th day | 19.1% (4/21)a (14.3% for primary keloid and 28.6% for recurred keloid) | 18 | Depigmentation and atrophy after IL (100%), infection (1), and flap necrosis (1) |
Our | 35 | 45 | Chinese (97.1%) Caucasian (2.9%) | 27.1 | F (85.7%) M (14.3%) | Lobe (71.1%) Helix (28.9%) | 17.8% (8/45) | Enucleation + core fillet flap | 6-MeV electron | 15/3 × 5 or 18/3 × 6; 1 Fr. in post-OP 24 h and 2 Fr. in post-OP 2–4 days | 6.7% (3/45) | 24.1 | 2.2% (1/45); seroma (1) |
